SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 335.58 |
| Enterprise Value ($M) | 328.97 |
| Book Value ($M) | -12.62 |
| Book Value / Share | -0.15 |
| Price / Book | -26.58 |
| NCAV ($M) | -12.62 |
| NCAV / Share | -0.15 |
| Price / NCAV | -26.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -4.70 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.37 |
| Current Ratio | 0.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.47 |
| Assets | 7.47 |
| Liabilities | 20.10 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.04 |
| Operating Income | -56.17 |
| Net Income | -56.24 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -31.10 |
| Cash from Investing | 0.00 |
| Cash from Financing | 32.78 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Glazer Capital, Llc | 6.41 | ||
| 13G | Beryl Capital Management LLC | 9.90 | ||
| 13D/A | Fortress Biotech, Inc. | 11.20 | 0.27 | |
| 13G/A | Armistice Capital, Llc | 9.99 | 14.05 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 68,084 | 564,756 | 12.06 | |
| 189,615 | 1,299,967 | 14.59 | |
| 98,504 | 1,021,409 | 9.64 | |
| 187,437 | 1,657,802 | 11.31 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CGEN – Compugen Ltd. | CGTX – Cognition Therapeutics, Inc. |
| CING – Cingulate Inc. | CLDX – Celldex Therapeutics, Inc. |
| CLNN – Clene Inc. |
Financial data and stock pages provided by
Fintel.io